Showing results (291-300 of 327) with videos related to

Sort By:
Pageof 33
RMD Open|May 6, 2022
Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countriesFlorian Lucasson, Uta Kiltz, Umut Kalyoncu, et al.
Annals of Medicine|June 30, 2025
Diagnostic pathway for cardiac amyloidosis from the healthcare professional's perspective: results from the French DIAM-ATTR surveySilvia Oghina, Damien Legallois, Fabien Hyafil, et al.
Annals of the Rheumatic Diseases|November 17, 2018
Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countriesClémence Gorlier, Ana-Maria Orbai, Déborah Puyraimond-Zemmour, et al.
Rheumatology (Oxford, England)|January 3, 2025
Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP studyClementina López-Medina, Clémence Gorlier, Ana-Maria Orbai, et al.
Arthritis Care & Research|October 15, 2019
Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen CountriesAna-Maria Orbai, Jamie Perin, Clémence Gorlier, et al.
Annals of the Rheumatic Diseases|October 29, 2010
The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotypeKaren Dawidowicz, Yannick Allanore, Mickaël Guedj, et al.
Rheumatology (Oxford, England)|November 24, 2020
Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparisonJean-Guillaume Letarouilly, Benoît Flachaire, Céline Labadie, et al.
Annals of the Rheumatic Diseases|December 25, 2012
Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registryJacques-Eric Gottenberg, Gael Cinquetti, Claire Larroche, et al.
Joint Bone Spine|May 1, 2012
Abatacept therapy and safety managementThao Pham, Hervé Bachelez, Jean-Marie Berthelot, et al.
Drugs & Aging|June 19, 2015
Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and FrailtyNigel Arden, Pascal Richette, Cyrus Cooper, et al.
Pageof 33